The immune system is both a source of malignancies and a tool for cancer therapy. The Immunology/lmmunotherapy Program (IMM) supports basic and clinical research to increase the understanding and control of (1) the immune response to cancer and (2) the ways hematopoietic cell development and its dysregulation can be used to treat hematologic malignancies. IMM Program members approach this two-faceted goal through three scientific Themes: (1) Development and Optimization of Antigen-Directed Immunotherapeutics;(2) Positive and Negative Regulation of the Quality of Anti-Tumor Immunity. (3) Control of Hematopoiesis and Hematologic Malignancies. These Themes include outstanding basic science investigations, as well as highly collaborative translational initiatives to develop clinical trials based on this research. Program Co-Leader, Victor Engelhard, PhD, is internationally recognized for his work in tumor antigen identification and induction of tumor-specific CD8 T cell responses. Program Co-leader, Craig Slingluff, MD, has made major contributions to cancer immunotherapy through both laboratory research and investigator-initiated clinical trials. The Program consists of 27 Full Members and 3 Associate Members from six departments in the School of Medicine. Total extramural funding for the Program exceeds $17 million, including $4 million from the National Cancer Institute (NCI). Program Members have produced 293 cancer-relevant publications, of which 21% were inter-programmatic and 19% were intra-programmatic since the last renewal. The Program supports research in progress presentations and seminars to engender new directions and collaborations;Pilot funding to encourage development of promising collaborations and ideas;and an Immune Monitoring Laboratory to facilitate clinical research. Seventeen investigator-initiated clinical trials led by Program Members, including two ECOG trials and three additional multicenter trials, have enrolled patients across six cancer histologies and evaluated peptide vaccines, cytokines, and antibodies. These trials test hypotheses arising from laboratory science and also bring tissue to the laboratories to investigate cellular processes and molecular mechanisms to explain the clinical findings. This Program provides a firm foundation for continued advances in both understanding of the immune system and utilizing that knowledge to improve immunotherapy and treatment of hematologic malignancies.

Public Health Relevance

The immune system can be used to treat cancer. It also can be a source of cancer. The goals of the Immunology/lmmunotherapy Program are to understand how to enhance and utilize the therapeutic uses of the immune system, and identify the ways its malignant potential can be eliminated

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-22
Application #
8566491
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
22
Fiscal Year
2013
Total Cost
$30,142
Indirect Cost
$12,304
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Heuslein, Joshua L; Murrell, Kelsey P; Leiphart, Ryan J et al. (2016) Vascular growth responses to chronic arterial occlusion are unaffected by myeloid specific focal adhesion kinase (FAK) deletion. Sci Rep 6:27029
Ma, Zhenjun; Kim, Youngchul; Hu, Feifang et al. (2016) Point success rate for patient therapeutic response prediction by continuous biomarker scores. Stat Methods Med Res 25:1638-47
Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother 65:1201-12
Pelkofski, Elizabeth; Stine, Jessica; Wages, Nolan A et al. (2016) Cervical Cancer in Women Aged 35 Years and Younger. Clin Ther 38:459-66
Showalter, Timothy N; Camacho, Fabian; Cantrell, Leigh A et al. (2016) Determinants of Quality Care and Mortality for Patients With Locally Advanced Cervical Cancer in Virginia. Medicine (Baltimore) 95:e2913
Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunol Immunother 65:1189-99
Cross, A M; Wilson, A L; Guerrero, M S et al. (2016) Breast cancer antiestrogen resistance 3-p130(Cas) interactions promote adhesion disassembly and invasion in breast cancer cells. Oncogene 35:5850-5859
Kolpaczynska, Milena; DeRosa, Christopher A; Morris, William A et al. (2016) Thienyl Difluoroboron β-Diketonates in Solution and Polylactide Media. Aust J Chem 69:537-545
Sloane, Hillary S; Landers, James P; Kelly, Kimberly A (2016) Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors. J Mol Diagn 18:546-53
Cheng, Bei; He, Huacheng; Huang, Tao et al. (2016) Gold Nanosphere Gated Mesoporous Silica Nanoparticle Responsive to Near-Infrared Light and Redox Potential as a Theranostic Platform for Cancer Therapy. J Biomed Nanotechnol 12:435-49

Showing the most recent 10 out of 413 publications